Canagliflozin - Latest Advances

Endocrinology: What You May Have Missed in 2025.

Journal: Annals of internal medicine

Published: April 13, 2026

Alcoholic Ketoacidosis Accompanied by Acute Gastric Dilation in a Patient with type 2 Diabetes on an SGLT2 Inhibitor and Chronic Alcoholic Abuse.

Journal: Internal medicine (Tokyo, Japan)

Published: April 08, 2026

Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post hoc analysis of the CANVAS and CREDENCE trials.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: March 16, 2026

Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.

Journal: Pulmonology

Published: March 10, 2026

SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis.

Journal: JAMA network open

Published: February 23, 2026

Canagliflozin alleviates hyperandrogen-induced granulosa cell ferroptosis in polycystic ovary syndrome mice by activating the AMPK/GSK3β/NRF2 pathway.

Journal: The Journal of steroid biochemistry and molecular biology

Published: January 26, 2026

Mitigation of Ischemia/Reperfusion-Induced Acute Kidney Injury by Canagliflozin Is Associated with Altered Mitochondrial Dynamics and Reduced Proliferation in Swine.

Journal: Biomolecules

Published: January 21, 2026

Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis.

Journal: Medical sciences (Basel, Switzerland)

Published: January 20, 2026

SGLT1 and SGLT2 Modulation in Antidiabetic Therapy-Comparative Insights into Gliflozins and Natural Compounds Resveratrol and Viniferin.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 11, 2026

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Lipid Modulation in Heart Failure: A Narrative Review.

Journal: Cureus

Published: December 20, 2025

Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials.

Journal: International journal of molecular sciences

Published: December 17, 2025

NRF2-mediated anti-ferroptotic pathways in diabetic cardiomyopathy: Mechanistic insights, therapeutic advances, and challenges in cardiovascular protection.

Journal: Current problems in cardiology

Published: December 12, 2025